KalVista Pharmaceuticals (NASDAQ: KALV) furnishes Q2 2025 results press release

Rhea-AI Filing Summary

KalVista Pharmaceuticals, Inc. filed a current report to share its financial results for the fiscal quarter ended July 31, 2025. The results are contained in a press release furnished as Exhibit 99.1.

The company specifies that this earnings information is furnished under Item 2.02 of the Exchange Act, not deemed filed, and it is signed on behalf of the company by Chief Executive Officer Benjamin L. Palleiko.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001348911 0001348911 2025-09-11 2025-09-11 0001348911 dei:FormerAddressMember 2025-09-11 2025-09-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2025

KALVISTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-36830		20-0915291
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

200 Crossing Boulevard
Framingham, Massachusetts		01702
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 999-0075

55 Cambridge Parkway

Suite 901E

Cambridge, Massachusetts 02142

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		KALV		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On September 11, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) reported its financial results for the fiscal quarter ended July 31, 2025. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.

The information furnished with Item 2.02 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press release dated September 11, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						KALVISTA PHARMACEUTICALS, INC.
Date: September 11, 2025				By:		/s/ Benjamin L. Palleiko
						Benjamin L. Palleiko Chief Executive Officer

FAQ

What did KalVista Pharmaceuticals (KALV) disclose in this 8-K filing?

KalVista Pharmaceuticals disclosed that it has reported financial results for the fiscal quarter ended July 31, 2025. Those results are provided in a separate press release, which is attached to the filing as Exhibit 99.1 and furnished under Item 2.02.

Which period do KalVista Pharmaceuticals (KALV) results in this 8-K cover?

The results discussed in this 8-K cover KalVista Pharmaceuticals’ fiscal quarter ended July 31, 2025. The detailed financial information for that quarter appears in the company’s press release, which is included with the report as Exhibit 99.1.

How are KalVista Pharmaceuticals (KALV) earnings treated under the Exchange Act in this 8-K?

The earnings information is treated as “furnished,” not “filed,” under Section 18 of the Exchange Act. KalVista states that Item 2.02 and Exhibit 99.1 are not subject to Section 18 liabilities, nor incorporated into other filings unless specifically referenced.

What exhibits are attached to KalVista Pharmaceuticals (KALV) September 11, 2025 8-K?

Two exhibits are attached: Exhibit 99.1, which is a press release dated September 11, 2025 containing quarterly financial results, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL version of the report.

Who signed the KalVista Pharmaceuticals (KALV) 8-K reporting quarterly results?

The 8-K was signed on behalf of KalVista Pharmaceuticals by Benjamin L. Palleiko. He is identified in the document as the company’s Chief Executive Officer, executing the report pursuant to the requirements of the Securities Exchange Act of 1934.